A recent article lauding a so-called "looming wave of new generic pills," like many similar articles, fails to paint the bigger picture: that generics, while an important part of the healthcare system, ultimately play a limited role for patients.
Most Recent Posts
A few weeks ago, as I was visiting my family, I took one look at my two-year-old niece and said to my sister, "Mary's diaper needs changing."
There's a geek-blog site I check out periodically. It mostly writes about science fiction and popular culture, but occasionally it takes an interesting look at real developments in the sciences and medicine.
You should check-out the piece by Ken Thorpe that recently ran in U.S. News & World Report's Health section. The piece is entitled: Health Reform That Passes the Buck Is Short-Sighted.
David Brooks has a typically thoughtful column in today's New York Times. Brooks takes a look at the roll of healthcare costs in our budget debate and opines:
When discussing progress associated with medical innovation, we like to mention both life-saving and life-enhancing medicines. Why? Because so many debilitating chronic conditions may not be life-threatening, but the patients who live with them still deserve the best that healthcare has to offer.
Monday, we discussed how policies that undercut the biopharmaceutical research sector could lead to huge job losses, with an annual reduction in sector revenue of $20 billion potentially leading to as many as 260,000 lost jobs.